logo-loader
viewValiRx PLC

ValiRx Plc enjoying strong industry interest in its cancer treatments

George Morris, chief operations officer at ValiRx Plc (LON:VAL), updates Proactive's Andrew Scott on developments across the company's portfolio.

Morris says advanced conversations are continuing with possible partners as they look to press ahead with the development of their flagship VAL401 lung cancer candidate.

Quick facts: ValiRx PLC

Price: 0.145 GBX

AIM:VAL
Market: AIM
Market Cap: £1.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

RNS

Placing & Issue of Equity

7 hours, 57 minutes ago

Price Monitoring Extension

5 days, 4 hours ago

Half-year Report

2 weeks, 4 days ago

Company Update

2 weeks, 6 days ago

VAL201 Update

on 10/9/19

2 min read